Q3: In individuals with a first psychotic episode with full remission, how long should antipsychotic drug treatment be continued after remission in order to allow for the best outcomes?
This paper examines the extent to which health workers differ in their willingness to work in rural areas and the reasons for these differences, based on the data collected in Rwanda analysed individually and in combination with data from Ethiopia.
Clinical guideline, Methods, Evidence and Recommendations
In this guideline the following is covered: information needs of people with chronic hep
titis B and their carers; where children, young people and adults with chronic hepatitis B a-
should be assessed; assessment of liver disease, includi...ng the use of non-invasive tests and genotype testing; criteria for offering antiviral treatment; the efficacy, safety and cost effectiveness of currently available treatments; selection of first-line therapy; management of treatment failure or drug resistance; prophylactic treatment during im-
munosuppressive therapy; and monitoring for treatment response
more
The objectives of this guidance document are to:
1. Strengthen the capacity of country teams to effectively scale up and manage programmes to address severe acute malnutrition
2. Extend the geographic reach of quality treatment for SAM to all vulnerable communities in need
3. Maximize... access to appropriate and quality treatment for SAM among all eligible children in the community at all times
4. Aid the formulation and implementation of national policies and strategies that support objectives 1 to 3
5. Aid the creation of an enabling environment that supports objectives 1 to 3 through advocacy, documentation of successful practices, support for operational research, mobilization of resources and collaboration with partners
more
The purpose of this manual is to provide a resource for training to increase understanding of Health in All Policies (HiAP) by health and other professionals. It is anticipated that the material in this manual will form the basis of two- or three-day workshops, which will:
• Bu...ild capacity to promote, implement and evaluate HiAP;
• Encourage engagement and collaboration across sectors;
• Facilitate the exchange of experiences and lessons learned;
• Promote regional and global collaboration on HiAP; and
• Promote dissemination of skills to develop training courses for trainers.
more
Conflict, in its active or latent forms, is everywhere. The COVID-19 pandemic has demonstrated that public health emergencies can strike any country at any time. Given the universality of and interconnections between conflict, humanitarian crises, and public health emergencies, practitioners trained... in one sector or the other are being called upon to understand how to navigate all of these emergencies at once.
more
Diploma Program
For the Ethiopian Health Center Team
International Review of the Red Cross Volume 91 Number 874 June 2009
Male and Female Respondents Interviewed Along the Central and the Eastern Mediterranean Routes in 2017
9,483 surveys conducted with migrants in Italy, Bulgaria, Greece, Hungary, Kosovo, Montenegro, Romania, Serbia and The former Yugoslav Republic of Macedonia, in 2017
Mental health disorders remain widely under-reported — in our section on Data Quality & Definitions we discuss the challenges of dealing with this data. Figures presented in this entry should be taken as estimates of mental health disorder prevalence — they do not strictly reflect diagnosis data... (which would provide the global perspective on diagnosis, rather than actual prevalence differences), but are imputed from a combination of medical, epidemiological data, surveys and meta-regression modelling where raw data is unavailable. Further information can be found here.
Accessed April 15, 2019
more
World Health Organization, Food and Agriculture Organization of the United Nations & World Organisation for Animal Health. (2021). Antimicrobial resistance and the United Nations sustainable development cooperation framework: guidance for United Nations country teams. World Health Organization
Hypertension and COVID-19: Scientific report - 17 June 2021
Trustworthy, evidence-based health guidelines form the basis of national policies affecting both patients and health-care workers. Emphasizing the link between robust evidence and people’s trust in their health systems, Dr Hans Henri P. Kluge, WHO Regional Director for Europe said at the launch ev...ent, “Trust and transformation are key words for us, especially when we talk about improving and strengthening our health systems. Transformation should first and foremost serve the interests of patients and health-care workers”.
While it is not always easy to demonstrate the immediate effect of guidelines on people’s health, there is no viable alternative to utilizing guidelines based on the best available evidence.
Yet, developing robust guidelines remains a challenge for most countries. “Guidelines need to be both simple to use and timely, they need to address people’s real needs, especially at the local level, and should ultimately reflect the resources available,” said Dr Natasha Azzopardi-Muscat, Director, Country Health Policies and Systems, WHO/Europe. “This means that any successful guideline needs to be adjusted and adapted to local contexts and realities.”
more
Summary of key informant interviews with representatives of organizations providing, funding, or supporting WASH services to refugee populations
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte...d with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
more